Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroblastoma 3Lung Neoplasms 3Gallbladder Neoplasms 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Mesothelioma, Malignant 2Klatskin Tumor 2Ganglioneuroblastoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Testicular Neoplasms 1Seminoma 1Sarcoma 1Pinealoma 1

Interventions

sodium thiosulfate 2ebselen 1Sodium Chloride 1Saline Solution 1Ringer's Lactate 1Platinum 1Ofloxacin 1Magnetic Resonance Spectroscopy 1Hyaluronic Acid 1Hearing 1Cisplatin 1Acetylcysteine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hearing Loss × Platinum × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡